[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564264":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":31,"centralContacts":32,"locations":38,"responsibleParty":168,"collaborators":31,"id":170,"slug":171,"hasResults":172,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":31,"eligibilityCriteria":175,"healthyVolunteers":172,"sex":176,"minAge":177,"maxAge":31,"enrollmentInfo":178,"targetDuration":31,"studyType":181,"phases":182,"briefSummary":184,"conditions":185,"keywords":193,"overallStatus":41,"whyStopped":31,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":217},{"fullName":5,"class":6},"Arcellx, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"anito-cel","EXPERIMENTAL","Single dose of anito-cel cells infused intravenously",[13,14],"Biological: anito-cel","Drug: Standard Lymphodepletion regimen",[16,23],{"type":17,"name":9,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain",[9],[21,22],"anitocabtagene autoleucel","CART-ddBCMA",{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Standard Lymphodepletion regimen","Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion",[9],[29,30],"Cyclophosphamide","Fludarabine",null,[33],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Clinical Information","CONTACT","240-327-0379","clinical@arcellx.com",[39,53,62,71,81,91,101,110,119,129,139,149,159],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":31},"UCLA Medical Center","RECRUITING","Los Angeles","California","90095","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-118.24368,34.05223,{"lat":51,"lon":50},{"facility":54,"status":41,"city":55,"state":43,"zip":56,"country":45,"countryCode":46,"cosmosGeoPoint":57,"geoPoint":61,"contacts":31},"University of California, Irvine","Orange","92602",{"type":48,"coordinates":58},[59,60],-117.85311,33.78779,{"lat":60,"lon":59},{"facility":63,"status":41,"city":64,"state":43,"zip":65,"country":45,"countryCode":46,"cosmosGeoPoint":66,"geoPoint":70,"contacts":31},"Stanford Hospital","Palo Alto","94305",{"type":48,"coordinates":67},[68,69],-122.14302,37.44188,{"lat":69,"lon":68},{"facility":72,"status":41,"city":73,"state":74,"zip":75,"country":45,"countryCode":46,"cosmosGeoPoint":76,"geoPoint":80,"contacts":31},"University of South Florida - Carol and Frank Morsani Center of Advanced Healthcare","Tampa","Florida","33612",{"type":48,"coordinates":77},[78,79],-82.45843,27.94752,{"lat":79,"lon":78},{"facility":82,"status":41,"city":83,"state":84,"zip":85,"country":45,"countryCode":46,"cosmosGeoPoint":86,"geoPoint":90,"contacts":31},"Karmanos Cancer Institute","Detroit","Michigan","48201",{"type":48,"coordinates":87},[88,89],-83.04575,42.33143,{"lat":89,"lon":88},{"facility":92,"status":41,"city":93,"state":94,"zip":95,"country":45,"countryCode":46,"cosmosGeoPoint":96,"geoPoint":100,"contacts":31},"University of Minnesota Delaware Clinical Research Unit","Minneapolis","Minnesota","55414",{"type":48,"coordinates":97},[98,99],-93.26384,44.97997,{"lat":99,"lon":98},{"facility":102,"status":41,"city":103,"state":94,"zip":104,"country":45,"countryCode":46,"cosmosGeoPoint":105,"geoPoint":109,"contacts":31},"Mayo Clinic","Rochester","55905",{"type":48,"coordinates":106},[107,108],-92.4699,44.02163,{"lat":108,"lon":107},{"facility":111,"status":41,"city":112,"state":112,"zip":113,"country":45,"countryCode":46,"cosmosGeoPoint":114,"geoPoint":118,"contacts":31},"Columbia University Irving Medical Center","New York","10032",{"type":48,"coordinates":115},[116,117],-74.00597,40.71427,{"lat":117,"lon":116},{"facility":120,"status":41,"city":121,"state":122,"zip":123,"country":45,"countryCode":46,"cosmosGeoPoint":124,"geoPoint":128,"contacts":31},"Ohio State University","Columbus","Ohio","43221",{"type":48,"coordinates":125},[126,127],-82.99879,39.96118,{"lat":127,"lon":126},{"facility":130,"status":41,"city":131,"state":132,"zip":133,"country":45,"countryCode":46,"cosmosGeoPoint":134,"geoPoint":138,"contacts":31},"Oregon Health & Science University (OHSU)","Portland","Oregon","97239",{"type":48,"coordinates":135},[136,137],-122.67621,45.52345,{"lat":137,"lon":136},{"facility":140,"status":41,"city":141,"state":142,"zip":143,"country":45,"countryCode":46,"cosmosGeoPoint":144,"geoPoint":148,"contacts":31},"Temple University Hospital","Philadelphia","Pennsylvania","19140",{"type":48,"coordinates":145},[146,147],-75.16362,39.95238,{"lat":147,"lon":146},{"facility":150,"status":41,"city":151,"state":152,"zip":153,"country":45,"countryCode":46,"cosmosGeoPoint":154,"geoPoint":158,"contacts":31},"UT Southwestern Medical Center","Dallas","Texas","75390",{"type":48,"coordinates":155},[156,157],-96.80667,32.78306,{"lat":157,"lon":156},{"facility":160,"status":41,"city":161,"state":152,"zip":162,"country":45,"countryCode":46,"cosmosGeoPoint":163,"geoPoint":167,"contacts":31},"Houston Methodist Hospital","Houston","77030",{"type":48,"coordinates":164},[165,166],-95.36327,29.76328,{"lat":166,"lon":165},{"type":169,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100564264","phase-1-a-phase-1-study-of-anitocabtagene-autoleucel-for-the-treatment-of-subjects-with-non-oncology-plasma-cell-related-diseases-100564264",false,"NCT06626919","A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases","Inclusion Criteria:\n\n* Subject must be 18 years of age or older\n* Must have MGFA clinical classification Grades 2-4A at time of screening\n* Subject must have clinically active disease and requiring ongoing therapy for GMG\n* MG-ADL score 6 and QMG score \\>10 at screening\n* GMG specific autoantibodies must be above the reference laboratory ULN\n\nExclusion Criteria:\n\n* Subject is pregnant or breastfeeding\n* Treatment with Anti-CD20 agents, calcineurin inhibitors, FcRN inhibitors, azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide within the specified time frame prior to leukapheresis or prior to anito-cel infusion\n* Previous treatment with any gene therapy, chimeric antigen receptor therapy or T cell engager\n* Previous thymectomy within 6 months of screening\n* Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator","ALL","18 Years",{"count":179,"type":180},30,"ESTIMATED","INTERVENTIONAL",[183],"PHASE1","A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.",[186,187,188,189,190,191,192],"Muscular Diseases","Neuromuscular Manifestations","Autoimmune","Autoimmune Diseases","Autoimmune Diseases of the Nervous System","Myasthenia Gravis","Muscle Weakness",[194,195,196,197,198,199,200,201,191,202,203,204,205,206,207,21],"ARC-311","CART","CAR-T","BCMA","Anito-cel","Generalized Myasthenia Gravis","gMG","MG","non-oncology plasma cell","autoimmune","auto-antibody","chimeric antigen receptor","D-Domain chimeric antigen receptor","B-cell maturation antigen (BCMA)","2026-02-24",{"date":210,"type":211},"2026-02-25","ACTUAL",{"date":213,"type":211},"2025-04-30",{"date":215,"type":180},"2028-04",{"name":5,"class":6},13]